Data gathered: November 23
AI Stock Analysis - Pliant Therapeutics (PLRX)
Analysis generated November 11, 2024. Powered by Chat GPT.
Pliant Therapeutics is a biopharmaceutical company dedicated to discovering and developing novel therapies for the treatment of fibrosis. The company's approach involves targeting key pathways that regulate fibrosis to disrupt its progression and reverse tissue damage. With a robust pipeline and a commitment to innovation, Pliant Therapeutics is positioned within a highly specialized and impactful sector of the healthcare industry.
Stock Alerts - Pliant Therapeutics (PLRX)
 |
Pliant Therapeutics | November 15 Price is down by -5.5% in the last 24h. |
|
Pliant Therapeutics | November 14 Price is down by -5.1% in the last 24h. |
|
Pliant Therapeutics | November 12 Price is down by -5.1% in the last 24h. |
|
Pliant Therapeutics | November 8 Price is down by -5.5% in the last 24h. |
Alternative Data for Pliant Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 8 | Sign up | Sign up | Sign up |
| Sentiment | 97 | Sign up | Sign up | Sign up |
| Webpage traffic | 4,000 | Sign up | Sign up | Sign up |
| Employee Rating | 94 | Sign up | Sign up | Sign up |
| Google Trends | 11 | Sign up | Sign up | Sign up |
| Patents | 27 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 2 | Sign up | Sign up | Sign up |
| Facebook Followers | 77 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,178 | Sign up | Sign up | Sign up |
| Twitter Followers | 482 | Sign up | Sign up | Sign up |
| Twitter Mentions | 23 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 99 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 100 | Sign up | Sign up | Sign up |
| Linkedin Employees | 184 | Sign up | Sign up | Sign up |
About Pliant Therapeutics
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States.
| Price | $12.98 |
| Target Price | Sign up |
| Volume | 585,880 |
| Market Cap | $782M |
| Year Range | $10.52 - $15.7 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Pliant Therapeutics to Participate in Upcoming Investor EventsNovember 20 - Yahoo |
Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024November 18 - Finnhub |
|
|
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial ResultsNovember 7 - Yahoo |
 |
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Acquired by Harbor Capital Advisors Inc.November 7 - ETF Daily News |
|
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives $40.57 Average Target Price from BrokeragesNovember 5 - ETF Daily News |
Pliant Therapeutics to Participate in the Stifel Healthcare ConferenceNovember 5 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 14M | -14M | -58M | -62M | 0.000 |
| Q2 '24 | 0 | 15M | -15M | -56M | -60M | -0.920 |
| Q1 '24 | 0 | 15M | -16M | -47M | -52M | -0.780 |
| Q4 '23 | 4.8M | 14M | -14M | -41M | -47M | -0.690 |
| Q3 '23 | 0 | 15M | -16M | -41M | -48M | -0.700 |
Insider Transactions View All
| Ouimette Mike filed to sell 94,044 shares at $11.6. July 12 '24 |
| Hull Hans filed to sell 227,494 shares at $11.6. July 12 '24 |
| Coulie Bernard filed to sell 482,936 shares at $11.6. July 12 '24 |
| Cummings Keith Lamont filed to sell 282,115 shares at $11.6. July 12 '24 |
| Lefebvre Eric filed to sell 213,052 shares at $11.6. July 12 '24 |
Similar companies
Read more about Pliant Therapeutics (PLRX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Pliant Therapeutics?
The Market Cap of Pliant Therapeutics is $782M.
What is the current stock price of Pliant Therapeutics?
Currently, the price of one share of Pliant Therapeutics stock is $12.98.
How can I analyze the PLRX stock price chart for investment decisions?
The PLRX stock price chart above provides a comprehensive visual representation of Pliant Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Pliant Therapeutics shares. Our platform offers an up-to-date PLRX stock price chart, along with technical data analysis and alternative data insights.
Does PLRX offer dividends to its shareholders?
As of our latest update, Pliant Therapeutics (PLRX) does not offer dividends to its shareholders. Investors interested in Pliant Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Pliant Therapeutics?
Some of the similar stocks of Pliant Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.